

Resource Summary Report

Generated by [kravitz2](#) on Jul 30, 2026

The Immunology Database and Analysis Portal (ImmPort)

RRID:SCR_012804

Type: Tool

Proper Citation

The Immunology Database and Analysis Portal (ImmPort) (RRID:SCR_012804)

Resource Information

URL: <https://www.immport.org/home>

Proper Citation: The Immunology Database and Analysis Portal (ImmPort) (RRID:SCR_012804)

Description: Data sharing repository of clinical trials, associated mechanistic studies, and other basic and applied immunology research programs. Platform to store, analyze, and exchange datasets for immune mediated diseases. Data supplied by NIAID/DAIT funded investigators and genomic, proteomic, and other data relevant to research of these programs extracted from public databases. Provides data analysis tools and immunology focused ontology to advance research in basic and clinical immunology.

Abbreviations: ImmPort

Synonyms: Immunology Data and Analysis Portal, ImmPort system, ImmPort, Immunology Database and Analysis Portal

Resource Type: service resource, disease-related portal, data or information resource, data repository, database, ontology, controlled vocabulary, storage service resource, topical portal, portal

Defining Citation: [PMID:24791905](#)

Keywords: immunology, basic, clinical, data, share, store, analyze, exchange, dataset, immune, mediated, disease, analysis, tool, FASEB list

Related Condition: Immune mediated disease

Funding: NIH ;
NIAID ;
DAIT ;
NIAID HHSN266200400076C;

NIAID HHSN272201200028C

Resource Name: The Immunology Database and Analysis Portal (ImmPort)

Resource ID: SCR_012804

Alternate IDs: nlx_152691, r3d100012529

Alternate URLs: <http://www.immport.org/immport-open/public/home/home>,
<http://www.immport.org/>

Old URLs: <http://www.immport.org>

License URLs: <http://www.immport.org/immport-open/public/home/studySearch>,
<http://www.immport.org/immport-open/public/home/dataSubmission>

Record Creation Time: 20220129T080312+0000

Record Last Update: 20260729T044308+0000

Ratings and Alerts

No rating or validation information has been found for The Immunology Database and Analysis Portal (ImmPort).

No alerts have been found for The Immunology Database and Analysis Portal (ImmPort).

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 987 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Gou X, et al. (2026) Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells. Cancer research communications, 6(1), 5.

Luo M, et al. (2025) Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations. Cancer discovery, 15(3), 511.

Miao P, et al. (2025) Potential role of immune-related LncRNAs in prognosis of hepatocellular carcinoma: an integrative study. Discover oncology, 16(1), 1661.

Liao Z, et al. (2025) Identification of novel biomarkers for lupus nephritis. Biomolecules & biomedicine, 25(2), 406.

Jiang G, et al. (2025) Immune-related gene SOX10 affects ferroptosis in pancreatic cancer and facilitates tumor progression by targeting CMTM7-mediated Wnt/ β -catenin signaling pathway. *European journal of medical research*, 30(1), 5.

Song W, et al. (2025) Role of immune cell homeostasis in research and treatment response in hepatocellular carcinoma. *Clinical and experimental medicine*, 25(1), 42.

Guy MM, et al. (2025) SLC7A11 is a potential therapeutic target and prognostic biomarker correlated with immune cell infiltration in cervical cancer. *Discover oncology*, 16(1), 125.

Yi T, et al. (2025) Cuproptosis genes in predicting the occurrence of allergic rhinitis and pharmacological treatment. *PloS one*, 20(2), e0318511.

Hu F, et al. (2025) TLR7: A Key Prognostic Biomarker and Immunotherapeutic Target in Lung Adenocarcinoma. *Biomedicines*, 13(1).

Zhou EH, et al. (2025) Identifying and validating immunological biomarkers in obstructive sleep apnea through bioinformatics analysis. *Scientific reports*, 15(1), 9746.

Xiong W, et al. (2025) Advancing sepsis diagnosis and immunotherapy machine learning-driven identification of stable molecular biomarkers and therapeutic targets. *Scientific reports*, 15(1), 8333.

Lai Y, et al. (2025) Unveiling the crucial role of CD8⁺ T cell and endothelial cell interaction in rheumatoid arthritis through the integrated analysis of spatial transcriptomics and bulk/single-cell RNA-seq. *Journal of translational autoimmunity*, 10, 100285.

Lin SY, et al. (2025) Single-cell RNA sequencing reveals the heterogeneity and regulatory modules of cell-specific RNA-binding proteins in patients with systemic lupus erythematosus. *Biochemistry and biophysics reports*, 42, 101977.

Zhang Z, et al. (2025) A Novel Prognostic Signature Integrating Immune and Glycolytic Pathways for Enhanced Prognosis and Immunotherapy Prediction in Hepatocellular Carcinoma. *Journal of hepatocellular carcinoma*, 12, 805.

Qualls AE, et al. (2025) High-affinity CD16A polymorphism associated with reduced risk of severe COVID-19. *JCI insight*, 10(13).

Li Z, et al. (2025) Immune-associated molecular classification and prognosis signature of sepsis. *PloS one*, 20(6), e0326083.

Yang L, et al. (2025) Identification of natural killer cell-characteristic genes in atherosclerosis based on bioinformatics analysis. *Scientific reports*, 15(1), 17112.

Damjanovic AK, et al. (2025) Longitudinal analysis of passively and actively acquired SARS-CoV-2 antibodies in infants with repeat newborn screening samples. *Scientific reports*, 15(1), 23881.

Chi Y, et al. (2025) Multi-omics analysis reveals glutathione metabolism-related immune suppression and constructs a prognostic model in lung adenocarcinoma. *Frontiers in immunology*, 16, 1608407.

Zhou W, et al. (2025) Integrated analysis of single-cell and bulk RNA sequencing data to construct a risk assessment model based on plasma cell immune-related genes for predicting patient prognosis and therapeutic response in lung adenocarcinoma. *Oncology letters*, 29(6), 271.